To see the other types of publications on this topic, follow the link: Pylori therapy.

Journal articles on the topic 'Pylori therapy'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pylori therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

I.M., Saracino, Pavoni M., Zullo A., et al. "Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients." Antibiotics 9, no. 3 (2020): 121. http://dx.doi.org/10.3390/antibiotics9030121.

Full text
Abstract:
Helicobacter pylori (H. pylori) eradication fails in a definite amount of patients despite one or more therapeutic attempts. Curing these patients is progressively more difficult, due to development of antibiotic resistance. Current guidelines suggest testing antibiotic susceptibility in H. pylori isolates following two therapeutic attempts. Aim: to evaluate the development of antibiotic resistance, MIC values trends and therapeutic outcomes in patients who failed at least one H. pylori eradication therapy. Methods: consecutive patients, referred to perform upper gastrointestinal endoscopy (UG
APA, Harvard, Vancouver, ISO, and other styles
2

Fiorini, Giulia, Ilaria Maria Saracino, Angelo Zullo, et al. "Antibiotic Resistance and Therapy for H. pylori Infection in Immigrant Patients Treated in Italy." Journal of Clinical Medicine 9, no. 5 (2020): 1299. http://dx.doi.org/10.3390/jcm9051299.

Full text
Abstract:
Background: Helicobacter pylori (H. pylori) infection is the leading cause of both peptic ulcers and gastric tumors, including low-grade MALT-lymphoma and adenocarcinoma. Although it is decreasing in developed countries, H. pylori prevalence remains high in developing areas, mainly due to low socio-economic levels, and the potential consumption of contaminated water. Moreover, a different pattern of primary antibiotic resistance is expected in their H. pylori isolates, potentially affecting the efficacy of standard eradication therapies. Indeed, a previous study showed the eradication rate fol
APA, Harvard, Vancouver, ISO, and other styles
3

Zullo, Angelo, Vincenzo De Francesco, Annamaria Bellesia, et al. "Bismuth-based Quadruple Therapy Following H. pylori Eradication Failures: a Multicenter Study in Clinical Practice." Journal of Gastrointestinal and Liver Diseases 26, no. 3 (2017): 225–29. http://dx.doi.org/10.15403/jgld.2014.1121.263.zul.

Full text
Abstract:
Background & Aims: Helicobacter pylori (H. pylori) eradication in patients who failed one or more therapeutic attempts remains challenging. This study aimed to assess the efficacy of three-in-one capsules bismuth-based quadruple therapy (Pylera®) in these patients managed in clinical practice.
 Methods: This was a prospective, open-label, multicenter study enrolling consecutive, adult patients with persistent H. pylori infection following at least one standard therapy. All patients received a rescue quadruple therapy with Pylera (3 capsules four times daily) and esomeprazole 20 mg (1
APA, Harvard, Vancouver, ISO, and other styles
4

Di Ciaula, Agostino, Giuseppe Scaccianoce, Marino Venerito, et al. "Eradication Rates in Italian Subjects Heterogeneously Managed for Helicobacter pylori Infection. Time to Abandon Empiric Treatments in Southern Europe." Journal of Gastrointestinal and Liver Diseases 26, no. 2 (2017): 129–37. http://dx.doi.org/10.15403/jgld.2014.1121.262.itl.

Full text
Abstract:
Background & Aims: H. pylori eradication is strongly affected by various factors, including the ongoing antibiotic resistance. We describe a “real life” scenario in patients managed for H. pylori-related conditions, living in a southern Italian region (Apulia), an area with clarithromycin resistance >15%.Methods: 2,224 subjects were studied in two tertiary referral centers in Apulia. Analyses included: reason for referral, H. pylori infection rates (13C-urea breath test – UBT or upper endoscopy), and eradication rates following distinct regimens previously prescribed or prospectively pr
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Yang. "The overview of Clarithromycin treatment for Helicobacter pylori infection." Theoretical and Natural Science 46, no. 1 (2024): 142–48. http://dx.doi.org/10.54254/2753-8818/46/20240604.

Full text
Abstract:
Helicobacter pylori (H. pylori) is a Gram-negative bacillus that causes infections worldwide. Helicobacter pylori's drug resistance and infectivity are vital factors causing Helicobacter pylori infection. The virulence factors of Helicobacter pylori include acid escape virulence factors and epithelial cell colonizing factors, which can directly or indirectly cause chronic gastritis or gastric ulcer. As the resistance of Helicobacter pylori increases, a combination of multiple antibiotics is now the recommended therapy, and clarithromycin is one of them. The production process of clarithromycin
APA, Harvard, Vancouver, ISO, and other styles
6

Shahbazi, Shaahin, Zahra Vahdat Shariatpanahi, and Nourkhoda Sadeghifard. "Effect of Proton Pump Inhibitor Based Triple Therapy with Apple Cider Vinegar on Helicobacter Pylori Eradication." Galen Medical Journal 3, no. 2 (2014): 90–94. http://dx.doi.org/10.31661/gmj.v3i2.97.

Full text
Abstract:
Background: The purpose of this study was to evaluate the effect of apple cider vinegar plus PPI-based triple therapy on eradication of Helicobacter Pylori (H.pylori) infection.Materials and Methods: 116 patients with H. pylori infection were included in this randomized clinical trial. Patients in control group (n=59) received amoxicillin, clarithromycin, and pantaprazole twice daily. Patients in study group (57 patients) received the same regimen plus 30 mL of apple cider vinegar twice daily. The duration of therapy for study and control were 10 and 14 days respectively. Four weeks after the
APA, Harvard, Vancouver, ISO, and other styles
7

Chiba, N., A. Matisko, P. Sinclair, and ABR Thomson. "Helicobacter pylori: From Bench to Bedside." Canadian Journal of Gastroenterology 11, no. 7 (1997): 589–96. http://dx.doi.org/10.1155/1997/975469.

Full text
Abstract:
With the exponential increase in research in the field ofHelicobacter pyloria paradigm shift has occurred. It is now recognized thatH pyloriis a chronic infection of the stomach causing inflammation. Some patients remain asymptomatic, while others may develop dyspepsia, duodenal or gastric ulcer, gastric cancer or a mucosa-associated lymphoid tissue lymphoma. However, the role ofH pyloriin contributing to nonulcer dyspepsia or nonsteroidal anti-inflammatory drug gastropathy remains controversial. An effective vaccine againstH pyloriis years away. Major interest has focused on the questions "wh
APA, Harvard, Vancouver, ISO, and other styles
8

JJ, Ofman, Etchason J, and Fullerton S. "Helicobacter pylori Therapy." Nurse Practitioner 22, no. 5 (1997): 203. http://dx.doi.org/10.1097/00006205-199705000-00035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hartanto, Darius. "Helicobacter pylori Infection: Diagnosis and Therapy." Asian Journal of Medical Sciences 12, no. 4 (2021): 145–48. http://dx.doi.org/10.3126/ajms.v12i4.34506.

Full text
Abstract:
Helicobacter pylori (H. pylori) is a spiral shape gram-negative bacillus and have flagella for motility in mucus environment. H. pylori is microaerophilic organism, slow growing and requires complex growth media in vitro. H. pylori infecting more than 50% populations in worldwide. Prevalence of H. pylori infection is higher in developing countries compared to developed one, and indicates that socioeconomic and living standard may play a major role in the distribution. This study aims to provide an overview of how to diagnose and manage Helicobacter pylori infection. This study reviewed various
APA, Harvard, Vancouver, ISO, and other styles
10

Darius Hartanto. "Helicobacter pylori Infection: Diagnosis and Therapy." Asian Journal of Medical Sciences 12, no. 4 (2021): 145–48. https://doi.org/10.71152/ajms.v12i4.3582.

Full text
Abstract:
Helicobacter pylori (H. pylori) is a spiral shape gram-negative bacillus and have flagella for motility in mucus environment. H. pylori is microaerophilic organism, slow growing and requires complex growth media in vitro. H. pylori infecting more than 50% populations in worldwide. Prevalence of H. pylori infection is higher in developing countries compared to developed one, and indicates that socioeconomic and living standard may play a major role in the distribution. This study aims to provide an overview of how to diagnose and manage Helicobacter pylori infection. This study reviewed various
APA, Harvard, Vancouver, ISO, and other styles
11

De Francesco, Vincenzo, Angelo Zullo, Luigi Gatta, et al. "Rescue Therapies for H. pylori Infection in Italy." Antibiotics 10, no. 5 (2021): 525. http://dx.doi.org/10.3390/antibiotics10050525.

Full text
Abstract:
Background/Aims: Curing Helicobacter pylori infection remains challenging for clinicians, as no proposed first-line therapy achieves bacterial eradication in all treated patients so that several patients need two or more consecutive treatments. Bacterial culture with antibiotics susceptibility testing is largely unachievable in Italy, and empiric second-line and rescue therapies are generally used. This study aimed to identify what eradication regimens perform better in Italy, following first-line therapy failure. Methods: We performed a literature search on PubMed for studies on standard ther
APA, Harvard, Vancouver, ISO, and other styles
12

Eissa, Adil, and Saad Mirza. "The Relevance of Helicobacter pylori Infection to Iron Deficiency Anemia in Duhok City." Iraqi Journal of Medical Sciences 19, no. 1 (2021): 33–38. http://dx.doi.org/10.22578/ijms.19.1.5.

Full text
Abstract:
Background:Helicobacter pylori (H. pylori) infection had been criticized for many deleterious effects and had been amalgamated to iron deficiency by many authors, frequently based on correlative rather than direct relationship studies and often opposed by others. Objective: To evaluate the role of H. pylori infection in the etiology of iron deficiency anemia and to study the impact of the bacterial eradication on the response to iron therapy. Methods:The current study represents an interventional prospective study and involved 52 non-pregnant females with iron deficiency anemia. All patients w
APA, Harvard, Vancouver, ISO, and other styles
13

Нургалиева, Б. К. "ЭРАДИКАЦИОННАЯ ТЕРАПИЯ HELICOBACTER PYLORI". Наука и здравоохранение, № 1(27) (28 лютого 2025): 257–66. https://doi.org/10.34689/sh.2025.27.1.028.

Full text
Abstract:
Актуальность. Helicobacter pylori – бактерия, вызывающая хронический активный гастрит, пептическую язвенную болезнь, желудочную аденокарциному, МАЛТ-лимфому, атрофический гастрит. В последние годы в мире развилась устойчивость Helicobacter pylori к различным антибиотикам, что требует изучения вопроса и разработки новых схем терапии.) Цель: анализ современных подходов к эрадикационной терапии Helicobacter pylori по данным современной литературы. Стратегия поиска. Поиск научной литературы проводился в базах данных PubMed, Scopus, Web of Science и Cochrane Library за период с 2014 по 2024 год. Ис
APA, Harvard, Vancouver, ISO, and other styles
14

BOCIAN, KATARZYNA M., and ELŻBIETA K. JAGUSZTYN-KRYNICKA. "The Controversy over Anti-Helicobacter pylori Therapy." Polish Journal of Microbiology 61, no. 4 (2012): 239–46. http://dx.doi.org/10.33073/pjm-2012-033.

Full text
Abstract:
Helicobacter pylori is a Gram-negative spiral-shaped bacterium, member of epsilon-Proteobacteria specifically colonizing the gastric epithelium of humans. It causes one of the most common infections worldwide, affecting about half of the world's population. However, it should be noted that the prevalence of H. pylori, particularly in the Western world, has significantly decreased coinciding with an increase of some autoimmune and allergic diseases, such as asthma. Various epidemiological studies have also documented a negative association between H. pylori colonization and the presence of GERD
APA, Harvard, Vancouver, ISO, and other styles
15

Tongtawee, Taweesak, Wareeporn Wattanawongdon, and Theeraya Simawaranon. "Effects of periodontal therapy on eradication and recurrence of Helicobacter pylori infection after successful treatment." Journal of International Medical Research 47, no. 2 (2019): 875–83. http://dx.doi.org/10.1177/0300060518816158.

Full text
Abstract:
Objectives This study aimed to evaluate the effects of periodontal therapy on the efficacy of Helicobacter pylori eradication and on the recurrence of infection after eradication. Methods We conducted a prospective randomized trial on 698 gastric H. pylori-infected patients, of whom 347 received gastric H. pylori treatment alone and 342 received gastric H. pylori treatment plus periodontal therapy. The presence of H. pylori and associated virulence genes were detected by real-time polymerase chain reaction. Results After eradication of gastric H. pylori infection, the recurrence of gastric H.
APA, Harvard, Vancouver, ISO, and other styles
16

Saito, Yoshimasa, Kaho Konno, Moeka Sato, et al. "Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori." Cancers 11, no. 1 (2019): 116. http://dx.doi.org/10.3390/cancers11010116.

Full text
Abstract:
Eradication of Helicobacter pylori (H. pylori) is an effective strategy for preventing various gastrointestinal diseases such as gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. However, the eradication success rate is decreasing because of a recent increase in drug-resistant strains of H. pylori. Here, we evaluated the success rate of eradication therapy with vonoprazan (VPZ), a new potassium-competitive acid blocker, against drug-resistant H. pylori. In total, 793 patients who received H. pylori eradication therapy were investigated retrospectively. All underwent esomepr
APA, Harvard, Vancouver, ISO, and other styles
17

Rosania, Rosa, Ulrike Von Arnim, Alexander Link, et al. "Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study." Journal of Gastrointestinal and Liver Diseases 27, no. 2 (2018): 119–25. http://dx.doi.org/10.15403/jgld.2014.1121.272.hpy.

Full text
Abstract:
Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD.Methods: IBD outpatients with both Crohn´s disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H.
APA, Harvard, Vancouver, ISO, and other styles
18

Ivashkin, V. T., T. L. Lapina, I. V. Maev, et al. "Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for <i>H. pylori</i> Diagnostics and Treatment in Adults." Russian Journal of Gastroenterology, Hepatology, Coloproctology 32, no. 6 (2022): 72–93. http://dx.doi.org/10.22416/1382-4376-2022-32-6-72-93.

Full text
Abstract:
Aim: bring to the attention of practitioners indications for anti-Helicobacter therapy, methods and procedure for diagnostics and eradication therapy of Н. pylori infection.Key points. Chronic gastritis caused by Н. pylori infection, including asymptomatic persons, may be considered as an indication for eradication therapy of Н. pylori as etiological therapy and opportunistic screening for gastric cancer prevention. Indications, for obligatory anti-Helicobacter therapy include peptic ulcer, gastric MALT lymphoma, early gastric cancer (EGC) with endoscopic resection. H. pylori primary diagnosti
APA, Harvard, Vancouver, ISO, and other styles
19

Husain, Arif, and Shrish Bhatnagar. "Does H. pylori therapy augments the effect of iron therapy among children with iron deficiency anemia?" International Journal of Contemporary Pediatrics 7, no. 4 (2020): 831. http://dx.doi.org/10.18203/2349-3291.ijcp20201139.

Full text
Abstract:
Background: To assess beneficial effects of H. pylori therapy on children with pre-existing Iron Deficiency Anemia (IDA).Methods: A total of 218 consecutive patients with iron deficiency anemia (Hb 6-11 gm/dl) were invited to participate in the study. Patients underwent endoscopic biopsy and rapid urease test for H. pylori detection. A total of three groups were formed- Group I (n=13) - positive for H. pylori, underwent treatment for H. pylori therapy and IDA, Group II (n=16) - positive for H. pylori, underwent treatment for IDA only, Group III (n=101) - negative for H. pylori, underwent treat
APA, Harvard, Vancouver, ISO, and other styles
20

Asman, Rahmi, Yusri Dianne Jurnalis, and Zulda Musyarifah. "Helicobacter Pylori Infection in Children with the Rescue Therapy; A Case Report." International Journal of Research and Review 10, no. 1 (2023): 19–24. http://dx.doi.org/10.52403/ijrr.20230103.

Full text
Abstract:
Background: Helicobacter pylori infection affects more than half of the world population and it occurs generally in childhood. Risk factors include residence in a developing country, poor socio-economic status, overcrowding family, ethnic and genetic predisposition. There is a difficulty eradicating this bacterium due to its high antimicrobial resistance. We aim to discuss enforcement and management of Helicobacter pylori infection in children. Case Presentation: A 5 year 10 months old girl diagnosed with recurrent abdominal pain due to Helicobacter pylori infection. The patient often had recu
APA, Harvard, Vancouver, ISO, and other styles
21

Thuan, Nguyen Thi Minh, and Luong Thi Ha Vi. "Effcacy of quadruple therapy for the treatment of H. pylori infection at Gia Dinh people’s hospital." Tạp chí Y học Dự phòng 30, no. 4 (2021): 12–19. http://dx.doi.org/10.51403/0868-2836/2020/244.

Full text
Abstract:
Helicobacter pylori (H. pylori) infection is one of the most common chronic bacterial infections in the world. For the purpose of eradicating H. pylori, quadruple therapies are widely prescribed in patients infected with H. pylori. According to the Maastricht V Consensus Conference, in regions where the rate of resistance of H. pylori to CLR and MTZ is high such as Viet Nam, bismuth quadruple therapy is the first choice. However, bismuth also causes many side efects. The aim of this study was to assess the effectiveness of quadruple therapies on H. pylori infection at Gia Dinh people’s hospita
APA, Harvard, Vancouver, ISO, and other styles
22

Jeong, Su Jin, Kyoung Hwa Lee, Jie-Hyun Kim, Soon Young Park, and Young Goo Song. "Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model." Antibiotics 9, no. 8 (2020): 502. http://dx.doi.org/10.3390/antibiotics9080502.

Full text
Abstract:
Helicobacter pylori eradication rate with conventional standard therapy is decreasing owing to antibiotic resistance, necessitating novel antibacterial strategies against H. pylori. We evaluated the efficacy of a gentamicin-intercalated smectite hybrid (S-GM)-based treatment and analyzed fecal microbiome composition in H. pylori-infected mice. To evaluate anti-H. pylori efficacy, mice were divided into eight groups, and H. pylori eradication was assessed by a Campylobacter-like organism (CLO) test and PCR assay of H. pylori in gastric mucosa. One week after H. pylori eradication, pro-inflammat
APA, Harvard, Vancouver, ISO, and other styles
23

Kim, Ju Seok, Sun Hyung Kang, Hee Seok Moon, Jae Kyu Sung, and Hyun Yong Jeong. "Clinical Outcome of Eradication Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according toH. pyloriInfection Status." Gastroenterology Research and Practice 2016 (2016): 1–7. http://dx.doi.org/10.1155/2016/6794848.

Full text
Abstract:
Background. To evaluate the long-term outcome ofH. pylorieradication therapy for gastric MALT lymphoma according to the presence ofH. pyloriinfection.Methods. We retrospectively reviewed the medical records of patients between January 2001 and June 2014. The clinicopathologic characteristics and clinical outcomes were compared betweenH. pylori-positive andH. pylori-negative gastric MALT lymphoma groups.Results. Fifty-four patients were enrolled: 12H. pylori-negative and 42H. pylori-positive patients. The tumor was located more frequently in both the proximal and distal parts of the stomach (P=
APA, Harvard, Vancouver, ISO, and other styles
24

Hana, Mumtaz K. "Prevalence of H pylori in obese attending Obesity therapy Unit." AL-Kindy College Medical Journal 13, no. 2 (2019): 69–71. http://dx.doi.org/10.47723/kcmj.v13i2.98.

Full text
Abstract:
Background: Obesity is an increasing health problem in developed countries and has grown into a major global epidemic. Recent studies suggested colonization of the stomach by Hpylori might affect gastric expression of appetite- and satiety-related hormone and patients cured of H pylori infection gained weight. Obesity and Helicobacter pylori (H. pylori) are important because of the problems they lead and their frequency of occurrence.&#x0D; Objectives: To find out the prevalence of H. pylori infection in obese.&#x0D; Type of the study:A cross-sectional study&#x0D; Methods: A total of 32 obese
APA, Harvard, Vancouver, ISO, and other styles
25

Park, Chan Hyuk. "Helicobacter pylori Eradication and Gastric Cancer Prevention." Korean Journal of Helicobacter and Upper Gastrointestinal Research 21, no. 4 (2021): 267–74. http://dx.doi.org/10.7704/kjhugr.2021.0044.

Full text
Abstract:
Since Warren and Marshall demonstrated Helicobacter pylori (H. pylori) as a cause of gastritis in the early 1980s, H. pylori has been associated with various gastric diseases, including gastric ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, gastric adenoma, gastric adenocarcinoma, and hyperplastic gastric polyps. H. pylori eradication therapy can treat some associated diseases, including low-grade gastric MALT lymphoma, and significantly reduce the risk of peptic ulcer recurrence or progression of atrophic gastritis and intestinal metaplasia. In East Asia, where H. pylori an
APA, Harvard, Vancouver, ISO, and other styles
26

Kwack, WonGun, YunJeong Lim, ChiYeon Lim, and David Y. Graham. "High Dose Ilaprazole/Amoxicillin as First-Line Regimen forHelicobacter pyloriInfection in Korea." Gastroenterology Research and Practice 2016 (2016): 1–7. http://dx.doi.org/10.1155/2016/1648047.

Full text
Abstract:
Objective. The eradication rate ofHelicobacter pylori(H. pylori) following standard triple therapy has declined over the past few decades. This study has determined whether high dose dual therapy (PPI and amoxicillin) is adequate for eradicatingH. pyloriin Korea.Methods. This was an open-labeled study ofH. pyloriinfected treatment-naive patients. Subjects received dual therapy for 14 days: ilaprazole 40 mg tablets given twice a day and amoxicillin 750 mg tablets given 4 times a day. At the end of the therapy, the subjects visited the clinic to confirm compliance and monitor for any side effect
APA, Harvard, Vancouver, ISO, and other styles
27

Axon, A. T. R. "Campylobacter pylori – Therapy Review." Scandinavian Journal of Gastroenterology 24, sup160 (1989): 35–38. http://dx.doi.org/10.3109/00365528909091733.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

&NA;. "Anti-H. pylori therapy." Inpharma Weekly &NA;, no. 1148 (1998): 13. http://dx.doi.org/10.2165/00128413-199811480-00023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Lee, J. M., E. Deasy, and C. A. OʼMorain. "Helicobacter pylori eradication therapy." European Journal of Gastroenterology & Hepatology 12, no. 4 (2000): 433–37. http://dx.doi.org/10.1097/00042737-200012040-00011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

McLoughlin, Ramona, Istvan Racz, Martin Buckley, Humphrey J. O'Connor, and Colm O'Morain. "Therapy of Helicobacter pylori." Helicobacter 9, s1 (2004): 42–48. http://dx.doi.org/10.1111/j.1083-4389.2004.00251.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Graham, David Y., and Maria P. Dore. "Helicobacter pylori Therapy Demystified." Helicobacter 16, no. 5 (2011): 343–45. http://dx.doi.org/10.1111/j.1523-5378.2011.00891.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Sohail, Muhammad, Muhammad Fahim, Fahim Ullah Khan, et al. "Comparison of Efficacy of Conventional Triple Therapy and Non Bismuth Quadruple Therapy for Helicobacter Pylori Eradication." Pakistan Journal of Medical and Health Sciences 16, no. 7 (2022): 894–96. http://dx.doi.org/10.53350/pjmhs22167894.

Full text
Abstract:
Objective: To compare the efficacy of conventional triple therapy and non bismuth quadruple therapy for helicobacter pylori eradication. Setting: Gastroenterology Department, Lady Reading Hospital Peshawar. Study Design: Randomized control trial. Duration: 6 months 15th August, 2018 to 15th February 2019. Materials and Methods: In this study a total of 111 patients were observed. Patients were put in two groups, group A triple Helicobacter pylori eradication therapy and group B non-bismuth quadruple Helicobacter pylori eradication therapy. Randomization of patients to either treatment group wa
APA, Harvard, Vancouver, ISO, and other styles
33

Aryani, Fransisca Theresia, Agus Firmansyah, and Abdul Latief. "Comparison of combination of probiotic and standard therapy compared to standard therapy on eradication of Helicobacter pylori infection in children." Paediatrica Indonesiana 50, no. 1 (2016): 38. http://dx.doi.org/10.14238/pi50.1.2010.38-41.

Full text
Abstract:
Background Helicobacter pylori (H. pylori) infection is thought to be the etiology of chronic gastritis, peptic ulcer, and risk factor for gastric cancer. Management of H. pylori infection in children is associated with several problems such as compliance to therapy, untolerated side effects, and antibiotic resistance. Probiotic is reported to give beneficial effect in the management of H. pylori infection and there is no study yet on the effect of probiotic in eradication of H. pylori infection in Indonesian children.Objectives To study the effect of additional probiotic in the standard thera
APA, Harvard, Vancouver, ISO, and other styles
34

Kandyil, Roshini, Nadia S. Satya, and Robert A. Swerlick. "Chronic Pruritus Associated with Helicobacter Pylori." Journal of Cutaneous Medicine and Surgery 6, no. 2 (2002): 103–8. http://dx.doi.org/10.1177/120347540200600202.

Full text
Abstract:
Background: Helicobacter pylori is an established cause of gastritis and has been implicated in extradigestive diseases. Objective: To investigate the role of H. pylori in patients with unexplained refractory pruritus. Methods: Ten patients with severe pruritus unresponsive to conventional therapy were evaluated for active H. pylori infection by H. pylori serology followed by either esophagogastroduodenoscopy (EGD) or urea breath test. Of the 10 patients, 8 were found to have active infection. All 10 received anti- H. pylori antibiotic therapy and were reevaluated for relief of pruritus. Resul
APA, Harvard, Vancouver, ISO, and other styles
35

Zarić, S., B. Bojić, Lj Janković, et al. "Periodontal Therapy Improves Gastric Helicobacter pylori Eradication." Journal of Dental Research 88, no. 10 (2009): 946–50. http://dx.doi.org/10.1177/0022034509344559.

Full text
Abstract:
The oral cavity has been proposed as a reservoir for H. pylori that could be responsible for the refractoriness of gastric infection to triple therapy (antibiotics, antimicrobials, and proton pump inhibitors). The aim of this study was to evaluate the efficiency of combined periodontal and triple therapy vs. triple therapy alone, in gastric H. pylori eradication in persons with H. pylori in the subgingival biofilm. Individuals positive for H. pylori in their gastric and oral samples, as determined by nested PCR, were treated either with periodontal and triple therapy or with triple therapy alo
APA, Harvard, Vancouver, ISO, and other styles
36

Namiot, DB, K. Leszczyńska, A. Namiot, et al. "The influence of Helicobacter pylori eradication therapy on the presence of H. pylori antigens in dental plaque and saliva." Progress in Health Sciences 6, no. 1 (2016): 19–24. http://dx.doi.org/10.5604/01.3001.0009.5016.

Full text
Abstract:
Purpose: The aim of this study was to evaluate the presence of H. pylori antigens in the oral cavity (dental plaque and saliva) of patients undergoing systemic eradication therapy. Materials and methods: The study was conducted in 49 subjects with H. pylori stomach infection. H. pylori antigens in dental plaque and saliva were evaluated with immunological method. Results: In subjects with initial H. pylori oral infection, the presence of H. pylori antigens in the oral cavity 6 weeks after successful or unsuccessful H. pylori eradication therapy in the stomach was 47.0% and 50.0%, respectively.
APA, Harvard, Vancouver, ISO, and other styles
37

Rongli, Cui, and Zhou Liya. "Helicobacter pylori infection: an overview in 2013, focus on therapy." Chinese Medical Journal 127, no. 3 (2014): 568–73. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20132708.

Full text
Abstract:
Objective This article aimed to review the incidence of Helicobacter pylori (H. pylori) infection and its therapy. Data sources Relevant articles published in English were identified by searching in PubMed from 2000 to 2013, with keywords “H. pylori”. Important references from selected articles were also retrieved from Elsevier, Wiley, EBSCO, and SPRINGER. The Chinese articles published were searched from China National Knowledge Infrastructure (CNKI). Study selection Articles about “prevalence”, “gastric carcinoma”, “peptic ulcer”, “gastroesophageal reflux disease”, “functional dyspepsia”, “p
APA, Harvard, Vancouver, ISO, and other styles
38

Bakulina, Bakulina N. V., Savilova I. V. Savilova, Lutaenko E. A. Lutaenko, and Tsurtsumia D. B. Tsurtsumia. "Perspectives for the use of nanotechnologies in Helicobacter pylori eradication." Therapy 7_2023 (October 25, 2023): 168–75. http://dx.doi.org/10.18565/therapy.2023.7.168-175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Yoshinaga, Masahiro, Akira Ohtani, Satoru Tsuruta, et al. "Effect of Acid-Suppressive Therapy onHelicobactor pyloriProduction of Interleukin-8 in Gastric Mucosa." Canadian Journal of Gastroenterology 14, no. 4 (2000): 277–82. http://dx.doi.org/10.1155/2000/946382.

Full text
Abstract:
BACKGROUND: Recent studies have shown that acid-suppressive therapy increases the severity ofHelicobacter pylori- associated gastritis in the corpus.PURPOSE: To evaluate interleukin (IL)-8 production in the gastric corpus mucosa before and during acid-suppressive therapy inH pylori-infected patients.PATIENTS AND METHODS: Ten patients with reflux esophagitis (fiveH pylori-positive and fiveH pylori-negative) were treated with omeprazole 20 mg. Serum gastrin concentrations,H pyloricolonization density and mucosal IL-8 levels in the corpus were investigated at entry and two weeks after starting th
APA, Harvard, Vancouver, ISO, and other styles
40

Chen, Shasha, Weina Shen, Yuhuan Liu, Qiang Dong, and Yongquan Shi. "Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial." Chinese Medical Journal 136, no. 14 (2023): 1690–98. http://dx.doi.org/10.1097/cm9.0000000000002696.

Full text
Abstract:
Abstract Background: With the development of traditional Chinese medicine research, berberine has shown good efficacy and safety in the eradication of Helicobacter pylori (H. pylori). The present study aimed to evaluate the efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for the initial treatment of H. pylori. Methods: This study was a single-center, open-label, parallel, randomized controlled clinical trial. Patients with H. pylori infection were randomly (1:1:1) assigned to receive berberine triple therapy (berberine 500 mg, amoxicillin 1000 mg, vonopr
APA, Harvard, Vancouver, ISO, and other styles
41

Schanova, Natalya O., and Lyudmila V. Prokhorova. "Improvement of Helicobacter pylori eradication efficacy at stomach and duodenum peptic ulcers." Russian Journal of Gastroenterology, Hepatology, Coloproctology 26, no. 2 (2016): 11–18. http://dx.doi.org/10.22416/1382-4376-2016-26-2-11-18.

Full text
Abstract:
Aim of investigation. To estimate efficacy of the modified sequential therapy regimen of Helicobacter pylori (H. pylori) eradication (with addition of bismuth tripotassium dicitrate) at treatment of peptic ulcer of the stomach (PUS) and duodenum (PUD) of severe and complicated course in the Russian population. Material and methods. Original study included overall 105 patients with PUS and PUD with severe and complicated course of disease. The main group received modified sequential therapy regimen, the comparison group - standard triple mode. All patients underwent quantitative serological tes
APA, Harvard, Vancouver, ISO, and other styles
42

Lee, Tae Ho, Hang Yeon Jeong, Do Yeon An, et al. "Bamboo Salt and Triple Therapy Synergistically Inhibit Helicobacter pylori-Induced Gastritis In Vivo: A Preliminary Study." International Journal of Molecular Sciences 23, no. 22 (2022): 13997. http://dx.doi.org/10.3390/ijms232213997.

Full text
Abstract:
Helicobacter pylori infections are a major cause of gastrointestinal disorders, including gastric ulcers, gastritis, and gastric cancer. Triple therapy, using two antibiotics and a proton pump inhibitor, is recommended for the treatment of H. pylori infections. However, antibiotic resistance in H. pylori is an emerging issue. Bamboo salt, a traditional Korean salt made by baking solar sea salt in bamboo barrels, can ameliorate the symptoms of various gastrointestinal diseases. Herein, we compared the anti-H. pylori activity of triple therapy (clarithromycin, metronidazole, and omeprazole), sol
APA, Harvard, Vancouver, ISO, and other styles
43

Kanu, Joseph Edwin, and Jonathan Soldera. "Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis." World Journal of Gastroenterology 30, no. 9 (2024): 1213–23. http://dx.doi.org/10.3748/wjg.v30.i9.1213.

Full text
Abstract:
BACKGROUND Helicobacter pylori (H. pylori ) infects over half the global population, causing gastrointestinal diseases like dyspepsia, gastritis, duodenitis, peptic ulcers, G-MALT lymphoma, and gastric adenocarcinoma. Eradicating H. pylori is crucial for treating and preventing these conditions. While conventional proton pump inhibitor (PPI)-based triple therapy is effective, there’s growing interest in longer acid suppression therapies. Potassium competitive acid blocker (P-CAB) triple and dual therapy are new regimens for H. pylori eradication. Initially used in Asian populations, vonoprazan
APA, Harvard, Vancouver, ISO, and other styles
44

Lai, Hung-Hsiang, and Ming-Wei Lai. "Treatment of Pediatric Helicobacter pylori Infection." Antibiotics 11, no. 6 (2022): 757. http://dx.doi.org/10.3390/antibiotics11060757.

Full text
Abstract:
Helicobacter pylori infection can cause gastritis, gastric or duodenal ulcers, mucosa-associated lymphoid tissue lymphoma, gastric cancer, and extra-gastrointestinal manifestations. Ideal treatment should be guided by antibiotic susceptibility testing. However, this is not feasible in many regions, so the treatment generally relies on clinical experience and regional culture sensitivity profiles. We aimed to integrate the treatment of pediatric H. pylori infection through a systematic literature review. Databases including PubMed, Cochrane Library, EMBASE, and Scholar were searched using terms
APA, Harvard, Vancouver, ISO, and other styles
45

Sun, Yingchao, Mengjia Zhu, Lei Yue, and Weiling Hu. "Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy." Journal of Clinical Medicine 11, no. 23 (2022): 7040. http://dx.doi.org/10.3390/jcm11237040.

Full text
Abstract:
Helicobacter pylori (HP) infection is closely associated with the development of chronic gastritis, peptic ulcer, and gastric cancer. However, the resistance rate of H. pylori strains to antibiotics such as clarithromycin, metronidazole, and levofloxacin has increased significantly, resulting in a significant decrease in the eradication efficacy of commonly used regimens. Tetracycline has received the attention of domestic and foreign scholars because of its low resistance. The purpose of this review is to provide an update on the tetracycline-containing bismuth quadruple eradication therapy f
APA, Harvard, Vancouver, ISO, and other styles
46

Liang, Chia-Ming, Chih-Hsiung Hsu, Chi-Hsiang Chung, et al. "Risk for Irritable Bowel Syndrome in Patients with Helicobacter Pylori Infection: A Nationwide Population-Based Study Cohort Study in Taiwan." International Journal of Environmental Research and Public Health 17, no. 10 (2020): 3737. http://dx.doi.org/10.3390/ijerph17103737.

Full text
Abstract:
Background: The association between Helicobacter pylori (H. pylori) infection and the risk of developing irritable bowel syndrome (IBS) has yet to be investigated; thus, we conducted this nationwide cohort study to examine the association in patients from Taiwan. Methods: A total of approximately 2669 individuals with newly diagnosed H. pylori infection and 10,676 age- and sex-matched patients without a diagnosis of H. pylori infection from 2000 to 2013 were identified from Taiwan’s National Health Insurance Research Database. The Kaplan–Meier method was used to determine the cumulative incide
APA, Harvard, Vancouver, ISO, and other styles
47

Choi, Youn I., and Jun-Won Chung. "Helicobacter pylori Eradication in Patients Undergoing Gastrectomy: Diagnosis and Therapy." Korean Journal of Helicobacter and Upper Gastrointestinal Research 20, no. 3 (2020): 204–9. http://dx.doi.org/10.7704/kjhugr.2019.0037.

Full text
Abstract:
The role of &lt;i&gt;Helicobacter pylori&lt;/i&gt; (&lt;i&gt;H. pylori&lt;/i&gt;) eradication in patients undergoing gastrectomy for gastric cancer is unclear. Although European and Asian guidelines strongly recommend &lt;i&gt;H. pylori&lt;/i&gt; eradication in patients who undergo endoscopic resection for early gastric cancer, these guidelines do not specify the tests useful for diagnosing &lt;i&gt;H. pylori&lt;/i&gt; infection, the optimal timing and appropriate eradication regimens, and follow-up strategies in patients undergoing gastrectomy for gastric cancer. This review aims to update th
APA, Harvard, Vancouver, ISO, and other styles
48

Sheptulin, A. A., S. S. Kardasheva та A. A. Kurbatova. "Modern approaches to the choice of schemes for eradication of Helicobacter рylori infection (based on the materials of the consensus meeting "Maastricht-VI")". Clinical Medicine (Russian Journal) 101, № 11 (2023): 582–87. http://dx.doi.org/10.30629/0023-2149-2023-101-11-582-587.

Full text
Abstract:
The article presents an analysis of the provisions of the consensus meeting “Maastricht-VI”, dedicated to the treatment of Helicobacter pylori (H. pylori) infection. The expediency of preliminary testing for H. pylori sensitivity to antibiotics is emphasized. Since this strategy has not yet been implemented in everyday clinical practice, empirical therapy is often carried out based on the results of the assessment of H. pylori resistance to antibiotics in this region. The sequence of administration of eradication regimens of the 1st, 2nd, 3rd, 4th lines, optimal duration of treatment, new ther
APA, Harvard, Vancouver, ISO, and other styles
49

Ikuse, Tamaki, Masanori Toda, Kosuke Kashiwagi, et al. "Efficacy of Helicobacter pylori Eradication Therapy on Platelet Recovery in Pediatric Immune Thrombocytopenic Purpura-Case Series and a Systematic Review." Microorganisms 8, no. 10 (2020): 1457. http://dx.doi.org/10.3390/microorganisms8101457.

Full text
Abstract:
Evidence relating to the efficacy of Helicobacter pylori eradication therapy for chronic immune thrombocytopenic purpura (cITP) in childhood is inadequate. The aim of this retrospective study was to determine the efficacy of H. pylori eradication therapy for platelet response in pediatric patients with cITP in our hospital, and to perform a systematic review of previous reports about pediatric patients with cITP who were positive for H. pylori infection and were treated with H. pylori eradication therapy. Analysis of the data of pediatric patients with cITP in our hospital and a systematic rev
APA, Harvard, Vancouver, ISO, and other styles
50

Hussain, Tanveer, Shafqat Iqbal, Seemab Abid, Misbah Sattar, and Shahid Aziz. "Role of Probiotic as an Add-on Therapy in Eradicating Helicobacter Pylori Infection." Annals of King Edward Medical University 27, no. 4 (2022): 557–62. http://dx.doi.org/10.21649/akemu.v27i4.4890.

Full text
Abstract:
Background: To compare the Helicobacter pylori eradication rate with and without use of Probiotic in conjunction with standard triple regimen. Methods: The patients with symptomatology of Gastritis and Dyspepsia were enrolled for the study. The presence of Helicobacter pylori was confirmed with Urea breath test. The experimental group received probiotic along with triple regimen therapy, while the control group received only triple regimen therapy. After four weeks of completion of treatment, urea breath test was repeated for confirmation of Helicobacter pylori eradication. Patients with negat
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!